Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 19:42:56 - browse：5861

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images

LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.

The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.

While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Medicare coverage of Wegovy, once blocked, now looks possible

hotspot

WSS

Why scientists need input from humanists on sensitive research

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Intellia reports positive results for its CRISPR

John Green on his newest strategy for fighting tuberculosis

Medicare coverage of Wegovy, once blocked, now looks possible

Innovation in antibiotics is ailing. 'Brain drain' may kill it

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In Memoriam: Notable people who died in 2023

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Duchenne breakthrough therapy leaves behind pioneering families

RaDonda Vaught links Vanderbilt hospital issues to patient death

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Shifting the focus from loneliness to social health

Novavax promises a turnaround & Lilly roils the obesity market

Boston's new lab space is opening empty

entertainment

HIV drugs protect against transmission, even in unprotected sex

The Pandemic Treaty must support building strong health systems

EPA limits use of carcinogenic gas for sterilizing medical devices

Ebola: Gilead Sciences antiviral shows promise as new treatment

WuXi out of biotech trade group, U.S. and China relations to blame

HHS secretary Becerra pressed on Change HealthCare cyberattack

entertainment

entertainment

hotspot

leisure time